{
    "2018-05-02": [
        [
            {
                "time": "2018-04-26",
                "original_text": "MorphoSys Posts Wider Loss In Q1; Confirms 2018 Financial Guidance - Quick Facts",
                "features": {
                    "keywords": [
                        "wider loss",
                        "Q1",
                        "financial guidance"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-05-15",
                "original_text": "Sandoz Gets Complete Response Letter From FDA For Proposed Biosimilar Rituximab",
                "features": {
                    "keywords": [
                        "FDA",
                        "biosimilar",
                        "rituximab"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-05-03",
                "original_text": "What Lies Ahead for Ligand (LGND) This Earnings Season?",
                "features": {
                    "keywords": [
                        "earnings season",
                        "Ligand"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "VXUS, NSRGY, TSM, NVS: Large Inflows Detected at ETF",
                "features": {
                    "keywords": [
                        "large inflows",
                        "ETF"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-11",
                "original_text": "NVS and NVO: Which Has Higher Upside Potential?",
                "features": {
                    "keywords": [
                        "upside potential",
                        "NVS",
                        "NVO"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-09",
                "original_text": "These Pharma Stocks Offer the Most Upside Potential",
                "features": {
                    "keywords": [
                        "pharma stocks",
                        "upside potential"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-02",
                "original_text": "The Swiss Stock Market Inched Higher Ahead Of Fed Announcement",
                "features": {
                    "keywords": [
                        "Swiss stock market",
                        "Fed announcement"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-04",
                "original_text": "Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings",
                "features": {
                    "keywords": [
                        "SIGA",
                        "FDA panel backing",
                        "earnings"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-14",
                "original_text": "For Expensive New Drugs, Biopharma Should Make Money-Back Guarantees Mandatory",
                "features": {
                    "keywords": [
                        "expensive drugs",
                        "money-back guarantees"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biopharma"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-05-08",
                "original_text": "Here’s What’s Moving SIGA and Novartis",
                "features": {
                    "keywords": [
                        "SIGA",
                        "Novartis"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}